DK2622348T3 - Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e - Google Patents

Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e Download PDF

Info

Publication number
DK2622348T3
DK2622348T3 DK11767970.4T DK11767970T DK2622348T3 DK 2622348 T3 DK2622348 T3 DK 2622348T3 DK 11767970 T DK11767970 T DK 11767970T DK 2622348 T3 DK2622348 T3 DK 2622348T3
Authority
DK
Denmark
Prior art keywords
antibody
cancer
braf
sample
tissue
Prior art date
Application number
DK11767970.4T
Other languages
Danish (da)
English (en)
Inventor
Deimling Andreas Von
David Capper
Hanswalter Zentgraf
Original Assignee
Deutsches Krebsforsch
Univ Heidelberg Ruprecht Karls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Deutsches Krebsforsch, Univ Heidelberg Ruprecht Karls filed Critical Deutsches Krebsforsch
Application granted granted Critical
Publication of DK2622348T3 publication Critical patent/DK2622348T3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK11767970.4T 2010-09-30 2011-09-30 Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e DK2622348T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38815810P 2010-09-30 2010-09-30
US201161503950P 2011-07-01 2011-07-01
PCT/EP2011/067092 WO2012042009A1 (en) 2010-09-30 2011-09-30 Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e

Publications (1)

Publication Number Publication Date
DK2622348T3 true DK2622348T3 (en) 2015-12-14

Family

ID=44789447

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11767970.4T DK2622348T3 (en) 2010-09-30 2011-09-30 Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e

Country Status (9)

Country Link
US (1) US9297812B2 (enExample)
EP (1) EP2622348B1 (enExample)
JP (1) JP5893037B2 (enExample)
CN (1) CN103403550B (enExample)
AU (1) AU2011310096B2 (enExample)
CA (1) CA2813098C (enExample)
DK (1) DK2622348T3 (enExample)
ES (1) ES2554678T3 (enExample)
WO (1) WO2012042009A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172744B (zh) * 2012-09-28 2016-01-13 武汉纽斯特生物技术有限公司 特异性识别B-Raf突变蛋白的单克隆抗体、制备方法及其应用
JP6485854B2 (ja) * 2014-09-24 2019-03-20 国立研究開発法人国立循環器病研究センター 抗変異型プロテインｓ抗体、該抗体を含む診断用組成物、変異型ヒトプロテインｓの検出方法および該抗体を含むキット
US11040027B2 (en) 2017-01-17 2021-06-22 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US12364776B2 (en) 2017-06-29 2025-07-22 Korea Advanced Institute Of Science And Technology Ganglioglioma-induced animal model and a method for diagnosing and treating ganglioglioma and related diseases
CN110183535A (zh) * 2018-12-17 2019-08-30 南京基诺米医疗科技有限公司 鼠抗人braf v600e突变蛋白单克隆抗体制备及其免疫组化用途
CN111285935B (zh) * 2020-05-13 2020-09-11 方达医药技术(上海)有限公司 特异性检测braf基因突变的抗体及其在制备癌症检测试剂盒中的用途
AU2021378815A1 (en) * 2020-11-16 2023-06-29 Agilent Technologies, Inc. Chimeric anti-human braf v600e antibodies and methods for making and using them
JPWO2024090265A1 (enExample) * 2022-10-28 2024-05-02

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6735531B2 (en) * 1996-10-07 2004-05-11 Lab Vision Corporation Method and apparatus for automatic tissue staining
AU2003286447A1 (en) * 2003-10-16 2004-06-06 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Treatments for inhibiting development and progression of nevi and melanoma having braf mutations
WO2007002811A2 (en) * 2005-06-29 2007-01-04 The Wistar Institute Of Anatomy And Biology Methods and compositions for treating melanoma
CA2639416C (en) 2007-09-11 2019-12-31 F. Hoffmann-La Roche Ag Diagnostic test for susceptibility to b-raf kinase inhibitors
EP3399520B1 (en) 2007-09-11 2022-01-05 University of Massachusetts Insulin-like growth factor binding protein 7 for use in treatment of cancer

Also Published As

Publication number Publication date
CN103403550A (zh) 2013-11-20
CA2813098A1 (en) 2012-04-05
AU2011310096B2 (en) 2014-11-06
US20130266962A1 (en) 2013-10-10
AU2011310096A1 (en) 2013-04-18
EP2622348B1 (en) 2015-09-16
WO2012042009A1 (en) 2012-04-05
US9297812B2 (en) 2016-03-29
JP2013543117A (ja) 2013-11-28
EP2622348A1 (en) 2013-08-07
CN103403550B (zh) 2015-08-19
ES2554678T3 (es) 2015-12-22
JP5893037B2 (ja) 2016-03-23
CA2813098C (en) 2019-10-08

Similar Documents

Publication Publication Date Title
DK2622348T3 (en) Means and methods for diagnosing cancer using an antibody which specifically binds to braf v600e
EP2438442B1 (en) Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95
JP6075881B2 (ja) 乳癌のバイオマーカー
EP2638394B1 (en) Histone protein ubiquitination as a cancer biomarker
JP2012501440A (ja) 内分泌処置予測因子としてのａｎｌｎタンパク質
US20190154694A1 (en) Detection and treatment of cancer
EP2288721B1 (en) Treatment prediction involving hmgcr protein
Zhang et al. A novel BCMA immunohistochemistry assay reveals a heterogenous and dynamic BCMA expression profile in multiple myeloma
JP5798916B2 (ja) Ｈｍｇｃｒタンパク質に関係する処置予測
JP2013096783A (ja) 肺腺癌を判定するためのデータ検出方法、診断薬、及び診断用キット
EP3067698A1 (en) Pd-ecgf as biomarker of cancer
US20130143231A1 (en) MST1/STK4 PHOSPHO-THREONINE 120 (pMST-T120) ANTIBODY